ITK

Class

Oral ITK inhibitor

ITK (interleukin-2-inducible T-cell kinase) is a member of the Tec family of non-receptor tyrosine kinases expressed predominantly in T lymphocytes and natural killer cells. It sits just downstream of the T-cell receptor (TCR), where it is required to fully activate phospholipase C-gamma1, a step that converts receptor engagement into calcium flux, transcription factor activation, and cytokine gene expression. Because ITK is particularly important for the differentiation of T-helper-2 (Th2) cells and for sustaining proliferation signals in some malignant T-cell populations, inhibiting it has been explored both for allergic and inflammatory conditions driven by excess Th2 activity and for T-cell lymphomas whose growth depends on persistent TCR-like signaling. Oral small-molecule inhibitors target the kinase's ATP-binding site, blocking its enzymatic activity without requiring injection. A key rationale for selective ITK inhibition, rather than blocking T-cell activation more broadly, is that other Tec-family members can partially substitute for ITK in some T-cell subsets, so a targeted approach may dampen pathogenic signaling while leaving certain protective immune functions less affected. This mechanism is relevant across autoimmune, allergic, and T-cell cancer contexts wherever TCR-driven signaling sustains disease.